Janux Therapeutics JANX Balance Sheet (2020-2026)

NASDAQ JANX
$20.24 +0.44 (+2.22%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Janux Therapeutics Quarterly Balance Sheet

Periods 25 quarters
Latest Jun 2026

Janux Therapeutics reported total assets of $1007.65M and total liabilities of $79.67M for the quarter ended Jun 2026, down 2.4% year over year. This balance sheet covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Accumulated Depreciation
0.07M0.13M0.21M0.32M0.57M0.97M1.41M1.88M2.38M2.91M3.45M3.93M4.44M4.95M5.47M6.01M6.50M6.97M7.35M7.82M
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
348.12M35.58M55.13M58.40M64.75M51.43M30.36M33.70M17.15M19.20M212.80M14.66M26.75M430.61M73.74M52.45M48.39M52.33M51.83M27.77M
Receivables - NetNet Receivables
0.50M0.80M0.52M7.50M35.00M0.15M
Receivables - OtherOther Receivables
2.16M3.89M4.56M4.45M5.38M5.58M5.69M6.32M6.43M7.46M6.18M
Receivables
0.50M0.80M2.16M4.41M12.06M6.43M42.46M6.33M
Prepaid Assets
2.08M2.05M3.45M3.77M5.07M5.42M3.77M6.01M5.48M5.21M6.38M8.15M8.29M8.49M9.19M9.54M9.09M9.32M10.66M12.28M
Current Assets
389.59M377.02M364.65M358.06M344.33M332.44M321.40M309.30M355.19M349.24M658.67M661.94M666.32M1,033.67M1,023.34M1,005.55M998.09M975.89M1,002.05M983.34M
Non-Current Assets
Property, Plant & Equipment (Net)
1.12M1.41M2.66M3.52M6.51M7.09M7.20M7.38M7.32M7.00M6.52M5.94M5.37M4.86M4.95M4.69M4.31M3.85M3.55M3.26M
Other Non-Current Assets
0.14M0.82M0.82M0.82M1.43M1.39M1.61M2.43M2.31M2.51M2.52M2.64M2.82M2.88M2.79M2.69M2.63M2.61M3.94M2.91M
Non-Current Assets
1.50M2.81M3.94M27.30M31.43M31.57M31.56M32.20M31.66M31.17M30.32M29.47M28.70M27.85M27.43M26.66M26.68M25.68M26.18M24.32M
Assets
391.08M379.82M368.60M385.37M375.76M364.01M352.96M341.50M386.85M380.41M688.98M691.41M695.02M1,061.52M1,050.77M1,032.21M1,024.77M1,001.57M1,028.22M1,007.65M
Liabilities
Current Liabilities
Accounts Payables
3.61M2.46M1.94M3.00M2.87M2.16M2.05M1.91M2.50M2.42M2.25M1.25M2.46M4.03M2.35M3.48M3.40M4.97M3.38M3.02M
Payables
3.61M2.46M1.94M3.00M2.87M2.16M2.05M1.91M2.50M2.42M2.25M1.25M2.46M4.03M2.35M3.48M3.40M4.97M3.38M3.02M
Accumulated Expenses
2.03M3.78M5.07M4.04M7.24M8.18M7.74M9.22M6.83M7.39M5.81M8.57M13.02M11.68M13.34M16.03M22.16M17.63M15.48M19.51M
Other Accumulated Expenses
0.52M0.48M0.33M0.35M0.61M0.62M0.73M1.02M0.61M0.55M0.81M0.72M0.78M0.92M0.93M0.59M0.55M0.94M0.84M0.83M
Current Leases
0.21M0.19M0.15M0.09M0.76M1.36M1.41M1.46M1.52M1.57M1.63M1.69M1.75M1.81M1.87M2.28M2.39M2.47M2.55M
Current Deferred Revenue
5.26M5.16M4.65M5.37M5.91M5.41M4.93M5.34M3.65M1.71M0.97M0.09M37.59M35.07M
Total Current Liabilities
12.47M12.80M12.52M12.99M16.34M16.51M16.11M17.90M14.47M13.03M10.61M11.54M17.17M17.46M17.50M21.38M27.83M25.00M58.91M60.15M
Non-Current Liabilities
Non-Current Deffered Revenue
1.84M0.70M5.29M3.82M2.22M1.39M0.31M8.68M1.08M
Preferred Stock Liabilities
Operating Leases
0.02M23.27M24.09M24.54M24.18M23.82M23.43M23.02M22.61M22.19M21.74M21.28M20.80M20.32M20.38M19.75M19.10M18.44M
Total Liabilities
14.33M13.50M12.52M41.55M44.24M43.27M41.69M42.03M37.90M36.06M33.22M33.73M38.91M38.73M38.30M41.70M48.21M44.74M86.69M79.67M
Shareholder's Equity
Common Equity
376.75M366.33M356.08M343.81M331.51M320.74M311.26M299.47M348.95M344.35M655.76M657.68M656.10M1,022.78M1,012.47M990.52M976.55M956.82M941.53M927.98M
Liabilities and Shareholders Equity
391.08M379.82M368.60M385.37M375.76M364.01M352.96M341.50M386.85M380.41M688.98M691.41M695.02M1,061.52M1,050.77M1,032.21M1,024.77M1,001.57M1,028.22M1,007.65M
Retained Earnings
-34.00M-47.41M-60.82M-77.71M-94.41M-110.47M-127.93M-145.44M-157.00M-168.76M-183.52M-189.50M-217.54M-237.76M-261.30M-295.12M-319.44M-351.38M-375.74M-397.71M
Treasury Shares